PubMed

Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.

Qiao L, Hamamichi S, Caldwell KA, Caldwell GA, Yacoubian TA, Wilson S, Xie ZL, Speake LD, Parks R, Crabtree D, Liang Q, Crimmins S, Schneider L, Uchiyama Y, Iwatsubo T, Zhou Y, Peng L, Lu Y, Standaert DG, Walls KC, Shacka JJ, Roth KA, Zhang J.

Mol Brain. 2008 Nov 21;1(1):17.PMID: 19021916 [PubMed - in process]Related articlesFree article

Enhanced lysosomal pathology caused by beta-synuclein mutants linked to dementia with Lewy bodies.

Wei J, Fujita M, Nakai M, Waragai M, Watabe K, Akatsu H, Rockenstein E, Masliah E, Hashimoto M.

J Biol Chem. 2007 Sep 28;282(39):28904-14. Epub 2007 Jul 24.PMID: 17652097 [PubMed - indexed for MEDLINE]Related articlesFree article

Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?

Fujita M, Sekigawa A, Sekiyama K, Sugama S, Hashimoto M.

J Neurol. 2009 Aug;256 Suppl 3:286-92. Review.PMID: 19711118 [PubMed - indexed for MEDLINE]Related articles

Oxidative stress-induced phosphorylation, degradation and aggregation of alpha-synuclein are linked to upregulated CK2 and cathepsin D.

Takahashi M, Ko LW, Kulathingal J, Jiang P, Sevlever D, Yen SH.

Eur J Neurosci. 2007 Aug;26(4):863-74.PMID: 17714183 [PubMed - indexed for MEDLINE]Related articles

DJ-1 modulates alpha-synuclein aggregation state in a cellular model of oxidative stress: relevance for Parkinson's disease and involvement of HSP70.

Batelli S, Albani D, Rametta R, Polito L, Prato F, Pesaresi M, Negro A, Forloni G.

PLoS One. 2008 Apr 2;3(4):e1884.PMID: 18382667 [PubMed - indexed for MEDLINE]Related articlesFree article

Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.

Gerard M, Deleersnijder A, Daniëls V, Schreurs S, Munck S, Reumers V, Pottel H, Engelborghs Y, Van den Haute C, Taymans JM, Debyser Z, Baekelandt V.

J Neurosci. 2010 Feb 17;30(7):2454-63.PMID: 20164329 [PubMed - in process]Related articles

Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration.

Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM.

J Neurosci. 2008 Jul 23;28(30):7687-98.PMID: 18650345 [PubMed - indexed for MEDLINE]Related articlesFree article

Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain.

Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, Kirik D.

Brain. 2007 Mar;130(Pt 3):799-815. Epub 2007 Feb 15.PMID: 17303591 [PubMed - indexed for MEDLINE]Related articlesFree article

Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.

Chu Y, Dodiya H, Aebischer P, Olanow CW, Kordower JH.

Neurobiol Dis. 2009 Sep;35(3):385-98. Epub 2009 Jun 6.PMID: 19505575 [PubMed - indexed for MEDLINE]Related articles

Reciprocal effects of alpha-synuclein overexpression and proteasome inhibition in neuronal cells and tissue.

Dyllick-Brenzinger M, D'Souza CA, Dahlmann B, Kloetzel PM, Tandon A.

Neurotox Res. 2010 Apr;17(3):215-27. Epub 2009 Aug 4.PMID: 19653055 [PubMed - in process]Related articles

Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies.

Paleologou KE, Kragh CL, Mann DM, Salem SA, Al-Shami R, Allsop D, Hassan AH, Jensen PH, El-Agnaf OM.

Brain. 2009 Apr;132(Pt 4):1093-101. Epub 2009 Jan 20.PMID: 19155272 [PubMed - indexed for MEDLINE]Related articles

Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity.

Gitler AD, Chesi A, Geddie ML, Strathearn KE, Hamamichi S, Hill KJ, Caldwell KA, Caldwell GA, Cooper AA, Rochet JC, Lindquist S.

Nat Genet. 2009 Mar;41(3):308-15. Epub 2009 Feb 1.PMID: 19182805 [PubMed - indexed for MEDLINE]Related articlesFree article

The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis.

Gitler AD, Bevis BJ, Shorter J, Strathearn KE, Hamamichi S, Su LJ, Caldwell KA, Caldwell GA, Rochet JC, McCaffery JM, Barlowe C, Lindquist S.

Proc Natl Acad Sci U S A. 2008 Jan 8;105(1):145-50. Epub 2007 Dec 27.PMID: 18162536 [PubMed - indexed for MEDLINE]Related articlesFree article

Sensitive fluorescence polarization technique for rapid screening of alpha-synuclein oligomerization/fibrillization inhibitors.

Luk KC, Hyde EG, Trojanowski JQ, Lee VM.

Biochemistry. 2007 Nov 6;46(44):12522-9. Epub 2007 Oct 10.PMID: 17927212 [PubMed - indexed for MEDLINE]Related articles

Formation and development of Lewy pathology: a critical update.

Jellinger KA.

J Neurol. 2009 Aug;256 Suppl 3:270-9. Review.PMID: 19711116 [PubMed - indexed for MEDLINE]Related articles

Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation.

Outeiro TF, Klucken J, Strathearn KE, Liu F, Nguyen P, Rochet JC, Hyman BT, McLean PJ.

Biochem Biophys Res Commun. 2006 Dec 22;351(3):631-8. Epub 2006 Oct 26.PMID: 17081499 [PubMed - indexed for MEDLINE]Related articlesFree article

Insights into the effects of alpha-synuclein expression and proteasome inhibition on glutathione metabolism through a dynamic in silico model of Parkinson's disease: validation by cell culture data.

Vali S, Chinta SJ, Peng J, Sultana Z, Singh N, Sharma P, Sharada S, Andersen JK, Bharath MM.

Free Radic Biol Med. 2008 Nov 1;45(9):1290-301. Epub 2008 Aug 8.PMID: 18761401 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease.

Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, Schenk D.

Neuron. 2005 Jun 16;46(6):857-68.PMID: 15953415 [PubMed - indexed for MEDLINE]Related articles

A novel, high-efficiency cellular model of fibrillar alpha-synuclein inclusions and the examination of mutations that inhibit amyloid formation.

Waxman EA, Giasson BI.

J Neurochem. 2010 Feb 2. [Epub ahead of print]PMID: 20132485 [PubMed - as supplied by publisher]Related articles

Conditional transgenic mice expressing C-terminally truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons.

Daher JP, Ying M, Banerjee R, McDonald RS, Hahn MD, Yang L, Flint Beal M, Thomas B, Dawson VL, Dawson TM, Moore DJ.

Mol Neurodegener. 2009 Jul 24;4:34.PMID: 19630976 [PubMed - in process]Related articlesFree article